SCHEMBL6152265

SCHEMBL6152265

CN1C(CCc2ccccc2CN2CCOCC2)=C(C(=O)O)C(C)(c2c(Cl)cccc2Cl)C(C(=O)O)=C1CC(=O)N1CCN(C2CC3CCC(C2)N3C)CC1

nearest known ligand 0.38

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 4/20 0.37
KMT2A Q03164 4/20 0.37
HRH3 Q9Y5N1 5/20 0.36
CYP2A13 Q16696 2/20 0.35
CCR3 P51677 1/20 0.34
RAB9A P51151 1/20 0.33
P2RX7 Q99572 1/20 0.33
PLA2G7 Q13093 1/20 0.33
MGLL Q99685 1/20 0.33
ABHD6 Q9BV23 1/20 0.33
KDM4E B2RXH2 4/20 0.33
TSHR P16473 1/20 0.32
TDP1 Q9NUW8 1/20 0.32
ALDH1A1 P00352 2/20 0.32
L3MBTL1 Q9Y468 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6152996 0.91 POLB (0.34) HRH3CCR3KDM4ETSHRALDH1A1
SCHEMBL6152752 0.88 MEN1 (0.36) MEN1KMT2ARAB9AMGLLKDM4E
SCHEMBL6943073 0.87 CCR3 (0.37) MEN1KMT2ACCR3KDM4EALDH1A1
SCHEMBL6154290 0.86 CCR3 (0.35) MEN1KMT2ACCR3KDM4EALDH1A1
SCHEMBL6154565 0.85 CCR3 (0.34) MEN1KMT2ACCR3KDM4EALDH1A1
SCHEMBL9080882 0.85 SIGMAR1 (0.42) MEN1KMT2ACCR3KDM4EALDH1A1
SCHEMBL6154442 0.85 CCR3 (0.33) KMT2ACCR3P2RX7KDM4EALDH1A1
SCHEMBL6153099 0.84 CCR3 (0.33) MEN1KMT2ACCR3KDM4EALDH1A1
SCHEMBL6152354 0.84 CCR3 (0.33) CCR3KDM4EALDH1A1
SCHEMBL6153058 0.83 CCR3 (0.33) CCR3KDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6653313-B2 For treatment and prevention of inflammation, asthma, allergic rhinitis, pain and other disorders WARNER-LAMBERT COMPANY LLC 2003-11-25 US claimed
EP-1307449-A1 1,4-DIHYDROPYRIDINES AS BRADYKININ ANTAGONISTS PFIZER PHARMACEUTICALS INC. (JP) 2003-05-07 EP claimed
US-20020161006-A1 1,4-dihydropyridine compounds as bradykinin antagonists KAWAMURA MITSUHIRO (US) 2002-10-31 US claimed
WO-2002012235-A1 1,4-DIHYDROPYRIDINES AS BRADYKININ ANTAGONISTS PFIZER PHARMACEUTICALS INC. (JP) 2002-02-14 WO claimed
EP-1307449-B1 1,4-DIHYDROPYRIDINES AS BRADYKININ ANTAGONISTS PFIZER PHARMA (JP) 2005-12-07 EP disclosed
US-6653313-B2 For treatment and prevention of inflammation, asthma, allergic rhinitis, pain and other disorders WARNER-LAMBERT COMPANY LLC 2003-11-25 US disclosed
EP-1307449-A1 1,4-DIHYDROPYRIDINES AS BRADYKININ ANTAGONISTS PFIZER PHARMACEUTICALS INC. (JP) 2003-05-07 EP disclosed
US-20020161006-A1 1,4-dihydropyridine compounds as bradykinin antagonists KAWAMURA MITSUHIRO (US) 2002-10-31 US disclosed
WO-2002012235-A1 1,4-DIHYDROPYRIDINES AS BRADYKININ ANTAGONISTS PFIZER PHARMACEUTICALS INC. (JP) 2002-02-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020161006-A1 1,4-dihydropyridine compounds as bradykinin antagonists BDKRB1, BDKRB2, HRH4 MEN1 2435/4885KMT2A 1890/4885HRH3 6/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.